Literature DB >> 15305848

Pharmacokinetics and lung tissue concentrations of tulathromycin in swine.

H A Benchaoui1, M Nowakowski, J Sherington, T G Rowan, S J Sunderland.   

Abstract

The absolute bioavailability and lung tissue distribution of the triamilide antimicrobial, tulathromycin, were investigated in swine. Fifty-six pigs received 2.5 mg/kg of tulathromycin 10% formulation by either intramuscular (i.m.) or intravenous (i.v.) route in two studies: study A (10 pigs, i.m. and 10 pigs, i.v.) and study B (36 pigs, i.m.). After i.m. administration the mean maximum plasma concentration (C(max)) was 616 ng/mL, which was reached by 0.25 h postinjection (t(max)). The mean apparent elimination half-life (t(1/2)) in plasma was 75.6 h. After i.v. injection plasma clearance (Cl) was 181 mL/kg.h, the volume of distribution at steady-state (V(ss)) was 13.2 L/kg and the elimination t(1/2) was 67.5 h. The systemic bioavailability following i.m. administration was >87% and the ratio of lung drug concentration for i.m. vs. i.v. injection was > or =0.96. Following i.m. administration, a mean tulathromycin concentration of 2840 ng/g was detected in lung tissue at 12 h postdosing. The mean lung C(max) of 3470 ng/g was reached by 24 h postdose (t(max)). Mean lung drug concentrations after 6 and 10 days were 1700 and 1240 ng/g, respectively. The AUC(inf) was 61.4 times greater for the lung than for plasma. The apparent elimination t(1/2) for tulathromycin in the lung was 142 h (6 days). Following i.m. administration to pigs at 2.5 mg/kg body weight, tulathromycin was rapidly absorbed and highly bioavailable. The high distribution to lung and slow elimination following a single dose of tulathromycin, are desirable pharmacokinetic attributes for an antimicrobial drug indicated for the treatment of respiratory disease in swine.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15305848     DOI: 10.1111/j.1365-2885.2004.00586.x

Source DB:  PubMed          Journal:  J Vet Pharmacol Ther        ISSN: 0140-7783            Impact factor:   1.786


  17 in total

1.  Antimalarial activity of tulathromycin in a murine model of malaria.

Authors:  Nicolas Villarino; Joshua E Denny; Nathan W Schmidt
Journal:  Antimicrob Agents Chemother       Date:  2015-04-13       Impact factor: 5.191

2.  Comparative therapeutic effect of steroidal and non-steroidal anti-inflammatory drugs on pro-inflammatory cytokine production in water buffalo calves (Bubalus bubalis) naturally infected with bronchopneumonia: a randomized clinical trial.

Authors:  Mohamed Abdo Rizk; Motamed Elsayed Mahmoud; Shimaa Abd El-Salam El-Sayed; Doaa Salman
Journal:  Trop Anim Health Prod       Date:  2017-08-22       Impact factor: 1.559

3.  Effect of spiramycin and tulathromycin on abomasal emptying rate in milk-fed calves.

Authors:  Mehdi Rashnavadi; Mohammad Nouri; Mohammad R Haji Hajikolaei; Housain Najafzadeh; Peter D Constable
Journal:  Can J Vet Res       Date:  2014-01       Impact factor: 1.310

4.  Concentration of the macrolide antibiotic tulathromycin in broncho-alveolar cells is influenced by comedication of rifampicin in foals.

Authors:  Monica Venner; Jette Peters; Nina Höhensteiger; Birthe Schock; Alexa Bornhorst; Markus Grube; Ulrike Adam; Eberhard Scheuch; Werner Weitschies; Dieter Rosskopf; Heyo K Kroemer; Werner Siegmund
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2009-12-15       Impact factor: 3.000

5.  Pharmacokinetics of tulathromycin in healthy and neutropenic mice challenged intranasally with lipopolysaccharide from Escherichia coli.

Authors:  N Villarino; S A Brown; T Martín-Jiménez
Journal:  Antimicrob Agents Chemother       Date:  2012-05-14       Impact factor: 5.191

6.  Pharmacokinetic/Pharmacodynamic Modeling of Tulathromycin against Pasteurella multocida in a Porcine Tissue Cage Model.

Authors:  Qiaoyi Zhou; Guijun Zhang; Qin Wang; Wenguang Liu; Yan Huang; Pengling Yu; Yanqin Li; Huanzhong Ding; Binghu Fang
Journal:  Front Pharmacol       Date:  2017-06-28       Impact factor: 5.810

7.  Network analysis of temporal functionalities of the gut induced by perturbations in new-born piglets.

Authors:  Nirupama Benis; Dirkjan Schokker; Maria Suarez-Diez; Vitor A P Martins Dos Santos; Hauke Smidt; Mari A Smits
Journal:  BMC Genomics       Date:  2015-07-29       Impact factor: 3.969

8.  Effect of Tulathromycin on Colonization Resistance, Antimicrobial Resistance, and Virulence of Human Gut Microbiota in Chemostats.

Authors:  Haihong Hao; Shengxi Zhou; Guyue Cheng; Menghong Dai; Xu Wang; Zhenli Liu; Yulian Wang; Zonghui Yuan
Journal:  Front Microbiol       Date:  2016-04-08       Impact factor: 5.640

9.  The pharmacokinetic-pharmacodynamic modeling and cut-off values of tildipirosin against Haemophilus parasuis.

Authors:  Zhixin Lei; Qianying Liu; Bing Yang; Saeed Ahmed; Jiyue Cao; Qigai He
Journal:  Oncotarget       Date:  2017-12-07

10.  Pharmacokinetics and Pharmacodynamics of Tildipirosin Against Pasteurella multocida in a Murine Lung Infection Model.

Authors:  Dongping Zeng; Meizhen Sun; Zhoumeng Lin; Miao Li; Ronette Gehring; Zhenling Zeng
Journal:  Front Microbiol       Date:  2018-05-18       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.